Digital Content 
NEWS #PharmaBuzz
25 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/25/3048413/0/en/Novartis-to-present-new-data-at-AAN-including-seven-year-disability-outcomes-and-safety-analysis-of-Kesimpta-in-people-with-relapsing-multiple-sclerosis.html
12 Apr 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326
12 Apr 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326
20 Apr 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/04/20/2650654/0/en/Novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-Kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis.html
19 Apr 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis-301802531.html
08 Dec 2022
// EMA
https://www.ema.europa.eu/en/documents/overview/kesimpta-epar-medicine-overview_en.pdf
Share 